Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis. ...
Posted by Michael Wonder on 25 Jul 2017
Dr Steve Pearson on using health technology assessment to guide decision making
23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...
Posted by Michael Wonder on 25 Jul 2017
ICER seeks public comment on proposed value assessment framework for treatments that represent a potential major advance for serious ultra-rare conditions
25 July 2017 - ICER’s fundamental approach to value assessment remains constant with proposed changes for special circumstances. ...
Posted by Michael Wonder on 19 Jul 2017
Institute for Clinical and Economic Review to evaluate CAR-T therapies in upcoming report
19 July 2017 - Report tentatively expected to review axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis). ...
Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 11 Jul 2017
Institute for Clinical and Economic Review posts draft scoping document on voretigene neparvovec, first gene therapy submitted for FDA approval
10 July 2017 - Report expected to review clinical effectiveness, value of the therapy; Scoping Document will be open to ...
Posted by Michael Wonder on 28 Jun 2017
ICER evidence report on abuse deterrent opioids finds limited evidence to demonstrate real world impact on opioid abuse
28 June 2017 - With substantially higher costs for abuse-deterrent formulations, and uncertainty regarding their impact on abuse, diversion, and switching ...
Posted by Michael Wonder on 27 Jun 2017
The Institute for Clinical and Economic Review to collaborate with the Department of Veterans Affairs' Pharmacy Benefits Management Services Office
27 June 2017 - ICER drug assessment reports to support VA drug coverage and price negotiation with pharmaceutical companies to ...
Posted by Michael Wonder on 22 Jun 2017
Institute for Clinical and Economic Review releases final value assessment framework for 2017-2019
22 June 2017 - Responds to public comment and sets key parameters for evidence review methods and process for stakeholder engagement. ...
Posted by Michael Wonder on 20 Jun 2017
When cholesterol drugs cost $14,000, an insurance tug-of-war
19 June 2017 - Patients struggle to obtain PCSK9 inhibitors, a powerful class of drugs that lower bad cholesterol in difficult ...
Posted by Michael Wonder on 17 Jun 2017
Institute for Clinical and Economic Review report finds inadequate evidence to distinguish between anabolic therapies for osteoporosis
16 June 2017 - Cost-effectiveness analyses find prices too high to align with added benefit to patients. ...
Posted by Michael Wonder on 15 Jun 2017
Institute for Clinical and Economic Review to evaluate voretigene neparvovec in upcoming review
15 June 2017 - First gene therapy to be submitted for approval to FDA; potential for life-time benefits with single ...
Posted by Michael Wonder on 13 Jun 2017
Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab
13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...
Posted by Michael Wonder on 08 Jun 2017
Institute for Clinical and Economic Review's final report on treatments for atopic dermatitis provides policy recommendations to support appropriate patient access to dupilumab
8 June 2017 - Report analyses evidence on the comparative effectiveness of dupilumab, finds price well-aligned with added value for patients; ...